Tempus Labs Inc.

Industry

  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Technologies
      • Genomics-Proteomics
  • Services
  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
    • Disease Management
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing

Other Names/Subsidiaries

  • Ambry Genetics
See more in Biomedtracker

Latest on Tempus Labs Inc.

In Vivo

Financing Quarterly Statistics, Q4 2024

 
• By Deanna Kamienski and Maureen Riordan

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Medtech Insight

News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use

 
• By Brian Bossetta, Hannah Daniel, Reed Miller, Elizabeth Orr, and Marion Webb

iRhythm Reveals Third DoJ Subpoena Wearable cardiac monitor company iRhythm Technologies, Inc. is facing a subpoena from the US Department of Justice’s Consumer Protection Branch, the company announ

Scrip

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

Scrip

Deal Watch: Lilly Teams With Regor On Metabolic Disorders

 
• By Joseph Haas and Dexter Jie Yan

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Doubles Down On Metabolic Disorde